{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:25Z","timestamp":1772165785958,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:bold>S<\/jats:bold>\n                      econdary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome that requires prompt diagnosis and appropriate treatment. A risk-stratification model that could be used to identify high-risk pediatric patients with HLH who should be considered for second-line therapies, including salvage regimens and allogeneic hematopoietic cell transplantation (HCT), was developed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of 88 pediatric patients (median age 1.4\u2009years, range 0.2\u201315\u2009years) with non-malignancy associated secondary HLH were retrospectively reviewed. Treatment strategies included dexamethasone, etoposide, and cyclosporine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Survival analysis showed HLH patients with infections other than Epstein-Barr virus (EBV) and unknown causes experienced better 5-year overall survival (OS) than patients with HLH due to autoimmune disease, EBV or immunodeficiency (76% vs. 65, 33.3, 11%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). On multivariate analysis, among all patients, non-response at 8\u2009weeks was the most powerful predictor of poor OS. When treatment response was excluded, hemoglobin &lt;\u200960\u2009g\/L and albumin &lt;\u200925\u2009g\/L at diagnosis were associated with poor OS. In patients with EBV-HLH, hemoglobin &lt;\u200960\u2009g\/L at diagnosis was associated with poor OS. A prognostic risk score was established and weighted based on hazard ratios calculated for three parameters measured at diagnosis: hemoglobin &lt;\u200960\u2009g\/L (2 points), platelets &lt;\u200930\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L (1 point), albumin &lt;\u200925\u2009g\/L (2 points). Five-year OS of low-risk (score 0\u20131), intermediate-risk (score 2), and poor-risk (score\u2009\u2265\u20093) patients were 88, 38, and 22%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings indicate that clinicians should be aware of predictive factors at diagnosis and consider 8-week treatment response to identify patients with high-risk of disease progression and the need for second-line therapy and allogeneic HCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-020-02178-7","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T03:04:19Z","timestamp":1591671859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children"],"prefix":"10.1186","volume":"20","author":[{"given":"Hua","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enben","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"4","key":"2178_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","volume":"28","author":"GE Janka","year":"2014","unstructured":"Janka GE, Lehmberg K. Hemophagocytic syndromes. Blood Rev. 2014;28(4):135\u201342.","journal-title":"Blood Rev"},{"key":"2178_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","volume":"63","author":"GE Janka","year":"2012","unstructured":"Janka GE. Familial and acquired Hemophagocytic Lymphohistiocytosis. Annu Rev Med. 2012;63:233\u201346.","journal-title":"Annu Rev Med"},{"issue":"11","key":"2178_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","volume":"66","author":"MB Jordan","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the north American consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2178_CR4","first-page":"726","volume":"10","author":"RL Kleynberg","year":"2012","unstructured":"Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012;10(11):726\u201332.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"2178_CR5","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.clml.2018.06.014","volume":"18","author":"E Apodaca","year":"2018","unstructured":"Apodaca E, Rodr\u00edguez-Rodr\u00edguez S, Tuna-Aguilar EJ, et al. Prognostic factors and outcomes in adults with secondary Hemophagocytic Lymphohistiocytosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(10):e373\u201380.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"2","key":"2178_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2018.198655","volume":"14","author":"J Ho Yoon","year":"2019","unstructured":"Ho Yoon J, Soo Park S, Woo Jeon Y, et al. Treatment outcomes and prognostic factors of adult patients with non-malignancy associated secondary hemophagocytic lymphohistiocytosis. Haematologica. 2019;14(2):269\u201376.","journal-title":"Haematologica"},{"issue":"2","key":"2178_CR7","first-page":"197","volume":"10","author":"M Aric\u00f2","year":"1996","unstructured":"Aric\u00f2 M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10(2):197\u2013203.","journal-title":"Leukemia"},{"issue":"3","key":"2178_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1651-2227.2011.02501.x","volume":"101","author":"H Trottestam","year":"2012","unstructured":"Trottestam H, Bergl\u00f6f E, Horne A, et al. Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatr. 2012;101(3):313\u20138.","journal-title":"Acta Paediatr"},{"issue":"7","key":"2178_CR9","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367\u201373.","journal-title":"Blood"},{"issue":"5","key":"2178_CR10","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6(5):1508\u201317.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"2178_CR11","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne AC, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2178_CR12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3109\/23744235.2015.1082036","volume":"47","author":"SK Topp","year":"2015","unstructured":"Topp SK, Rosenfeldt V, Vestergaard H, et al. Clinical characteristics and laboratory findings in Danish children hospitalized with primary Epstein-Barr virus infection. Infect Dis (Lond). 2015;47(12):908\u201314.","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"2178_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5501\/wjv.v1.i1.31","volume":"1","author":"M De Paschale","year":"2012","unstructured":"De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol. 2012;1(1):31\u201343.","journal-title":"World J Virol"},{"issue":"2","key":"2178_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2018.198655","volume":"104","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Park SS, Jeon YW, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. Haematologica. 2019;104(2):269\u201376.","journal-title":"Haematologica"},{"issue":"2","key":"2178_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"M Esraa","year":"2020","unstructured":"Esraa M, Eloseily EM, Weiser P, et al. Benefit of Anakinra in treating pediatric secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2178_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","volume":"192","author":"TS Johnson","year":"2014","unstructured":"Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84\u201391.","journal-title":"J Immunol"},{"issue":"2","key":"2178_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s12032-011-9963-3","volume":"29","author":"M Machaczka","year":"2012","unstructured":"Machaczka M, Nahi H, Karbach H, et al. Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Med Oncol. 2012;29(2):1231\u20136.","journal-title":"Med Oncol"},{"issue":"4","key":"2178_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0022-3476(85)80072-X","volume":"106","author":"M Hadchouel","year":"1985","unstructured":"Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic,andneurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106(4):561\u20136.","journal-title":"J Pediatr"},{"issue":"5","key":"2178_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","volume":"29","author":"A Ravelli","year":"2015","unstructured":"Ravelli A, Davi S, Minoia F, et al. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29(5):927\u201341.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2178_CR20","volume":"10","author":"O Abughanimeh","year":"2018","unstructured":"Abughanimeh O, Qasrawi A, Abu Ghanimeh M. Hemophagocytic Lymphohistiocytosis complicating systemic Sarcoidosis. Cureus. 2018;10(6):e2838.","journal-title":"Cureus"},{"issue":"1","key":"2178_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clim.2014.09.008","volume":"155","author":"Y Faitelson","year":"2014","unstructured":"Faitelson Y, Grunebaum E. Hemophagocytic lymphohistiocytosis and primary immune deficiency disorders. Clin Immunol. 2014;155(1):118\u201325.","journal-title":"Clin Immunol"},{"issue":"7","key":"2178_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2014.121608","volume":"100","author":"SF Bode","year":"2015","unstructured":"Bode SF, Ammann S, Al-Herz W, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies:implications for differential diagnosis and pathogenesis. Haematologica. 2015;100(7):978\u201388.","journal-title":"Haematologica"},{"issue":"40","key":"2178_CR23","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1097\/MD.0000000000001692","volume":"94","author":"S Valade","year":"2015","unstructured":"Valade S, Azoulay E, Galicier L. Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis. Medicine (Baltimore). 2015;94(40):e1692.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2178_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"ZK Otrock","year":"2015","unstructured":"Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220\u20134.","journal-title":"Am J Hematol"},{"issue":"26","key":"2178_CR25","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154\u20137.","journal-title":"Blood"},{"key":"2178_CR26","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.clml.2017.02.017","volume":"17S","author":"ZK Otrock","year":"2017","unstructured":"Otrock ZK, Daver N, Kantarjian HM, et al. Diagnostic challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk. 2017;17S:S105\u201310.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-020-02178-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T19:24:17Z","timestamp":1623180257000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-020-02178-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2178"],"URL":"https:\/\/doi.org\/10.1186\/s12887-020-02178-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23890\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23890\/v2","asserted-by":"object"}]},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed with the approval of the Ethics Committee of the Affiliated University of Qingdao University (no: 20190113). The protocol was designed and the study was conducted according to the principles of the Declaration of Helsinki (1964). Written informed consent was obtained from all participants. Consent was obtained from a parent or guardian on behalf of any participants under the age of 16\u2009years.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}